UK approves Eli Lilly’s oral weight-loss pill orforglipron

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Eli Lilly’s orforglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, for the treatment of obesity in adults.

The approval covers the use of orforglipron as a once-daily oral therapy, providing an alternative to injectable GLP-1 drugs such as Lilly’s own Mounjaro and Zepbound, which are administered via subcutaneous injection. The pill is designed to mimic the action of natural hormones that regulate appetite and glucose metabolism, supporting weight loss through a non-invasive delivery method.

Lilly has not yet disclosed pricing or launch timelines for the UK market, but the company has previously indicated that it aims to make oral GLP-1 therapies widely accessible. The MHRA’s decision follows positive phase 3 trial results, which demonstrated statistically significant weight reduction in adults with obesity or overweight conditions with at least one weight-related comorbidity.

Analysts note that orforglipron could expand Lilly’s dominance in the obesity treatment market, where injectable GLP-1 drugs have already generated billions in revenue. The oral formulation may appeal to patients seeking convenience and those hesitant to use injectable therapies. Competitors, including Novo Nordisk and Pfizer, are also developing oral GLP-1 alternatives, though none have yet secured regulatory approval in major markets.

The approval underscores the UK’s role as a key market for novel obesity therapies, aligning with broader global trends in metabolic health innovation.